GAMMA Investing LLC Purchases 4,715 Shares of ADMA Biologics Inc (NASDAQ:ADMA)

GAMMA Investing LLC lifted its stake in ADMA Biologics Inc (NASDAQ:ADMA) by 251.6% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 6,589 shares of the biotechnology company’s stock after buying an additional 4,715 shares during the period. GAMMA Investing LLC’s holdings in ADMA Biologics were worth $131,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also made changes to their positions in the company. Raymond James Financial Inc. bought a new stake in shares of ADMA Biologics in the fourth quarter valued at approximately $19,076,000. JPMorgan Chase & Co. boosted its stake in shares of ADMA Biologics by 272.5% in the fourth quarter. JPMorgan Chase & Co. now owns 767,265 shares of the biotechnology company’s stock valued at $13,159,000 after buying an additional 561,310 shares during the period. Victory Capital Management Inc. boosted its stake in shares of ADMA Biologics by 52.8% in the fourth quarter. Victory Capital Management Inc. now owns 109,948 shares of the biotechnology company’s stock valued at $1,886,000 after buying an additional 38,002 shares during the period. Sei Investments Co. boosted its stake in shares of ADMA Biologics by 147.2% in the fourth quarter. Sei Investments Co. now owns 527,272 shares of the biotechnology company’s stock valued at $9,043,000 after buying an additional 314,013 shares during the period. Finally, Swiss National Bank boosted its stake in shares of ADMA Biologics by 6.6% in the fourth quarter. Swiss National Bank now owns 458,400 shares of the biotechnology company’s stock valued at $7,862,000 after buying an additional 28,500 shares during the period. 75.68% of the stock is currently owned by institutional investors.

ADMA Biologics Stock Up 0.9%

Shares of ADMA opened at $18.30 on Friday. ADMA Biologics Inc has a one year low of $10.21 and a one year high of $25.67. The company has a market cap of $4.37 billion, a P/E ratio of 21.52 and a beta of 0.43. The company has a debt-to-equity ratio of 0.22, a current ratio of 6.58 and a quick ratio of 3.36. The firm has a 50 day simple moving average of $20.24 and a two-hundred day simple moving average of $18.73.

ADMA Biologics (NASDAQ:ADMA) last announced its quarterly earnings results on Wednesday, May 7th. The biotechnology company reported $0.14 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.16 by ($0.02). The company had revenue of $114.80 million for the quarter, compared to analyst estimates of $116.40 million. ADMA Biologics had a return on equity of 47.16% and a net margin of 45.01%. The firm’s quarterly revenue was up 40.2% on a year-over-year basis. During the same quarter last year, the company posted $0.08 earnings per share. Research analysts forecast that ADMA Biologics Inc will post 0.51 EPS for the current fiscal year.

Insider Transactions at ADMA Biologics

In other news, Director Jerrold B. Grossman sold 10,000 shares of the company’s stock in a transaction on Monday, June 9th. The shares were sold at an average price of $21.31, for a total transaction of $213,100.00. Following the completion of the transaction, the director directly owned 478,194 shares in the company, valued at approximately $10,190,314.14. This represents a 2.05% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Lawrence P. Guiheen sold 20,000 shares of the company’s stock in a transaction on Monday, June 9th. The stock was sold at an average price of $20.96, for a total transaction of $419,200.00. Following the transaction, the director owned 94,830 shares of the company’s stock, valued at $1,987,636.80. This trade represents a 17.42% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 464,621 shares of company stock worth $9,644,269. Corporate insiders own 3.50% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have commented on ADMA. Wall Street Zen downgraded shares of ADMA Biologics from a “hold” rating to a “sell” rating in a research report on Friday, May 9th. Raymond James Financial boosted their price objective on shares of ADMA Biologics from $25.00 to $32.00 and gave the company a “strong-buy” rating in a research report on Thursday, May 8th.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.